AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06455176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar cleft Grafting from the iliac cancellous bone
Description: grafting using iliac cancellous bone
Study NCT05916040 — intervention group
Intervention type: DEVICE
Intervention: Radiotherapy with MRIdian with simultaneous integrated boost
Description: radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost
Study NCT05916040 — intervention group
Intervention type: OTHER
Intervention: Questionnaires before, during and after radiotherapy
Description: Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~* EORTC QLQ-C30~* EORTC QLQ-CR29~* Low Anterior Resection Syndrome Score (LARS) questionnaire~* Hospital Anxiety and Depression Scale (HADS) questionnaire
Study NCT04551495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles
Study NCT04551495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles
Study NCT04551495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
Study NCT04795531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study NCT04795531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo insulin icodec
Description: You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study NCT04795531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study NCT06226922 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06118502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to a different medication
Description: Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.
Study NCT06118502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued use of the same medication
Description: Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.
Study NCT06118502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to a harm reduction tobacco product
Description: Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
Study NCT04888676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Class II Restoration
Description: A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
Study NCT04888676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class II Restoration
Description: A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
Study NCT04795531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo insulin degludec
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study NCT05146349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minnesota RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
Study NCT05450328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Epoprostenol Sodium & Milrinone
Description: One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions.
Study NCT05544721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Study NCT05450328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions.
Study NCT06304649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cast or brace alternative
Description: Waterproof alternative to a cast or brace for broken bones
Study NCT04828798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the VIM Thalamic nuclei
Description: Deep brain stimulation of the thalamus, in a directional and nondirectional manner
Study NCT06451497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZM008
Description: Intravenous delivery
Study NCT05705518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete PF
Description: 3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product
Study NCT05705518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Relieva PF
Description: 3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product
Study NCT05705518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Optive Mega-3 PF
Description: 3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product
Study NCT05705518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVS Health Lubricant Eye Drop (PG 0.6%)
Description: 3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
Study NCT04990557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and ACE2 Knockout T Cells
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study NCT05647460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided screw holes locating guide and custom-made plates
Description: Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.
Study NCT05805670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga and Mindfulness
Description: Intervention is a noninvasive approach. The protocol is composed of 5 sessions containing simple yoga postures and meditation audio supports to listen to and 1 post-operative visit (24 hours after surgery)~The 5 sessions will be carried out 1 session/week from inclusion to the day before surgery
Study NCT06316713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One MORE (Spanish Adaptation)
Description: One MORE is a 2-hour adaptation of the manualized MORE program and will be divided into two, 1-hour segments. In the first segment, participants will be introduced to mindfulness and guided though a body scan practice, which directs participants to systematically shift attention from one part of the body to the next. Participants will also be guided through a mindful pain management practice in which they will learn to deconstruct pain into sensory, emotional, cognitive, and behavioral components. The second segment will focus on managing the negative thoughts and emotion that can amplify pain with mindful reappraisal, as well as learning to focus on increasing the positive emotions that can attenuate pain with mindful savoring.
Study NCT04996667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled nitric oxide (iNO)
Description: Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes.
Study NCT05647460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plates
Description: mobilize the broken segment first, Arch bar was made to achieve proper occlusion put the compression plate on the inferior border and remove it for further bending using plate pliers for further accommodation of the plate on the inferior border the fix it in place using compression and tension plate.
Study NCT04670796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX02
Description: subject receive one dose of HLX02
Study NCT04670796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Trastuzumab (Herceptin®)
Description: subject receive one dose of EU-sourced Trastuzumab (Herceptin®)
Study NCT04670796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Trastuzumab (Herceptin®)
Description: subject receive one dose of US-licensed Trastuzumab (Herceptin®)
Study NCT05604261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole sodium 40 mg
Description: Anaprazole sodium 2 tablets (20 mg/tablet) + Anaprazole sodium dummy tablets 1 tablet (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study NCT05604261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole sodium 60 mg
Description: Anaprazole sodium 3 tablets (20 mg/tablet) + Rabeprazole sodium dummy tablets 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study NCT05604261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole sodium 20 mg
Description: Anaprazole sodium dummy tablets 3 tablets (20 mg/tablet) + Rabeprazole sodium 2 tablets (10 mg/tablet) orally once daily within 30-60 minutes before breakfast for 8 weeks (after 4 weeks of continuous treatment, if endoscopy shows reflux esophagitis is cured, treatment is discontinued, into the safety follow-up period).
Study NCT06345768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Ball
Description: It is a ball 5-6 cm in size and not too hard. It will be given to both hands of the patients and they will be asked to count from 1 to 5. This application will be repeated for 15 minutes.
Study NCT05000983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PluroGel
Description: A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.)
Study NCT05000983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressing
Description: Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent).
Study NCT06417671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotics supplementation
Description: The participants will consume one capsule per day.
Study NCT06417671 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: The participants will consume one capsule per day.
Study NCT05685576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezotomed ridge splitting and osseodensification
Description: Ridge expansion using piezotomed ridge splitting and osseodensification
Study NCT05038033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Description: The IPT group sessions follow three phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbating disinhibited eating and anxiety symptoms. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors and warning signs for excessive weight gain, such as eating in response to negative affect as opposed to hunger, or feeling a sense of loss-of-control while eating. IPT focuses on psychoeducation and general skill-building that can be applied to different relationships within the framework of four interpersonal problem areas: interpersonal role disputes, role transitions, interpersonal deficits, and grief.
Study NCT05038033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Theory (CBT)
Description: The CBT program will be derived from Coping Cat, a manualized intervention for children and adolescents with elevated symptoms of anxiety. The group intervention builds skills for managing anxiety, in general, but with a focus on how anxiety prompts disinhibited eating, including attention to and restructuring of negative cognitions that perpetuate anxiety and behavioral exposure, rather than avoidance, of anxiety-provoking situations.
Study NCT05905341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07224826
Description: Small molecule cell cycle checkpoint inhibitor that targets CDK 2, 4, and 6, to be administered orally.
Study NCT05905341 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Competitive ER antagonist, to be administered by intramuscular injection (prefilled syringe).
Study NCT05834374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextual variation
Description: The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
Study NCT05834374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum affordances
Description: The participants are instructed to perform ultrasound guided needle puncture of the cavities using a 20 ml syringe and a 15 cm, 18 Gauge biopsy needle. When all the three cavities are emptied the participant receive a new cube with refilled balloons. The new cube is equivalent to the old apart from being rotated 180 degrees. The participant are given one hour to empty as many cavities as possible. They are encouraged to track the needle with ultrasound while in the cube. The transfer test is performed on a CVS mannikin. The GE HealthCare LOGIQTM e Ultrasound is used with a C1-5 RS probe with or without the GE HealthCare C1-5 non-sterile ultrasound needle guide for both the training session and the transfer tests.
Study NCT05636371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written Communication
Description: Written patient care updates provided to families of ICU patients each day
Study NCT04972253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Oral, dosage per protocol
Study NCT04838496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI Protocol
Description: FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks:~Dosing:~* Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by:~* Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV~* Day 3-14: rest days.~Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered.~In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age.
Study NCT06544889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen SPF 70
Description: Participants will topically apply sunscreen SPF 70
Study NCT04710394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study NCT04710394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smell Training
Description: Participants will be provided with 4 labeled jars, each containing an odor pre-impregnated cotton pad. Participants will sniff each scent for 10 seconds, twice daily, once in the morning and once in evening. The participant will take 30 seconds of rest between each scent. All participants will undergo this smell training regimen for 12 weeks.
Study NCT06483165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BE FAST Educational video
Description: A 1-minute educational video format using BE FAST. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
Study NCT06483165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: F.A.S.T. Educational Video
Description: A 1-minute educational video format using F.A.S.T. Each acronym will be visually displayed in the video and audio voice over of each letter and corresponding phrase will be audible in English. The look, feel, and messaging in each video will be the same except for the acronyms.
Study NCT04750161 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be given to participants. It is purely observational.
Study NCT05291533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality (VR) Mindfulness Program
Description: The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.
Study NCT04971928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: GSK3228836 will be administered
Study NCT05247203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: subcutaneous injection
Study NCT05247203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: A standard regimen consists of the following medication(s) (alone or in combination)：corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.